{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T04:57:11Z","timestamp":1794632231151,"version":"4.9.1"},"reference-count":17,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2005,9,27]],"date-time":"2005-09-27T00:00:00Z","timestamp":1127779200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2006,1]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>The aims of the study were to: (1) evaluate the gastrointestinal transit, release and absorption of budesonide from tablets with a new multimatrix formulation (MMX\u00ae) designed to release the drug throughout the whole colon, and (2) assess the influence of food on budesonide bioavailability.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Two phase\u2003I studies, each comprising 12\u2003healthy males, were performed. Gastrointestinal transit of <jats:sup>153<\/jats:sup>Sm\u2010labelled tablets containing 9\u2003mg budesonide was evaluated by means of pharmaco\u2010scintigraphy. The effect of food was tested by comparing plasma pharmacokinetics after intake of a high fat and high calorie breakfast with fasting controls.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> <jats:sup>153<\/jats:sup>Sm\u2010labelled tablets reached the ascending colon after a mean\u2003\u00b1\u2003SD 9.8\u2003\u00b1\u20036.9\u2003h. Initial tablet disintegration was observed in the ileum in 42% and the ascending and transverse colon in 33% of subjects. Ninety\u2010six per cent of the dose was absorbed into the systemic circulation during passage through the whole colon including the sigmoid. Food significantly decreased <jats:italic>C<\/jats:italic><jats:sub><jats:italic>max<\/jats:italic><\/jats:sub> values from 1429\u2003\u00b1\u20031014 to 1040\u2003\u00b1\u2003601\u2003pg\u2003mL<jats:sup>\u22121<\/jats:sup> (<jats:italic>P<\/jats:italic>\u2003=\u20030.028) and AUC values from 14\u2003814\u2003\u00b1\u200311\u2003254 to 13\u2003486\u2003\u00b1\u20039369 pg\u2003h<jats:sup>\u22121<\/jats:sup>\u2003mL<jats:sup>\u22121<\/jats:sup> (<jats:italic>P<\/jats:italic>\u2003=\u20030.008). Mean residence time and <jats:italic>t<\/jats:italic><jats:sub><jats:italic>max<\/jats:italic><\/jats:sub> increased by 12\u201329%. There was no drug accumulation after 1\u2003week of once daily oral administration of budesomide.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>MMX\u00ae\u2010budesonide tablets appear suitable for targeted colonic drug delivery. Transit parameters and low systemic bioavailability warrant further studies with the new formulation.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2125.2005.02517.x","type":"journal-article","created":{"date-parts":[[2005,12,8]],"date-time":"2005-12-08T14:18:36Z","timestamp":1134051516000},"page":"31-38","source":"Crossref","is-referenced-by-count":78,"title":["Gastrointestinal transit, release and plasma pharmacokinetics of a new oral budesonide formulation"],"prefix":"10.1111","volume":"61","author":[{"given":"M.","family":"Brunner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ziegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. F. D.","family":"Di Stefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Dehghanyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Kletter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Tschurlovits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Bozzella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Celasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Moro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Rusca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Dudczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,9,27]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra020831"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjgastroenterol.2003.11.001"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443120-00003"},{"issue":"59","key":"e_1_2_5_5_2","first-page":"1345","article-title":"German Budesonide Foam Study Group. Controlled, open, randomized multicenter trial comparing the effects of treatment on quality of life, safety and efficacy of budesonide foam and betamethasone enemas in patients with active distal ulcerative colitis","volume":"51","author":"Hammond A","year":"2004","journal-title":"Hepatogastroenterology"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-409X(00)00135-6"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00175865"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01445.x"},{"key":"e_1_2_5_9_2","unstructured":"http:\/\/www.fda.gov\/cder\/guidance\/5194fnl.pdf. Last accessed: 10 June 2005."},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200401000-00008"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01426.x"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200212000-00012"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1988.tb05220.x"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2001.00910.x"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1D059"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00697.x"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200409000-00012"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.1780339"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2005.02517.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2005.02517.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T22:08:55Z","timestamp":1697407735000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2005.02517.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9,27]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1]]}},"alternative-id":["10.1111\/j.1365-2125.2005.02517.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2005.02517.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,9,27]]}}}